Zhenghui Jiang, MD
Gastroenterology · Boston, MANPI 1053605477
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $3,124 of the $3,835 with a category attached, or 81.5%. Boehringer Ingelheim accounts for 86.0% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2019 at $3,676 and has fallen 98.8% since, to $44 in 2025.
Across 7 payments — averaging $547.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$3K
- Gilead$377
- Novo Nordisk$159
Across 5 payments — averaging $68,050 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$210K
- Gilead$130K
What the payments were for
- Consulting fees$3,12481%
- Travel & lodging$1404%
- Food & beverage$3198%
- Gifts$2527%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 3 | $3,299 |
| Gilead | 2 | $377 |
| Novo Nordisk | 2 | $159 |
How this compares
$3,835 in reported general payments places this provider in the 70th percentile of 579 gastroenterology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RezdiffraResmetirom | 12 | $47,133 |
| VemlidyTenofovir Alafenamide | 20 | $27,956 |
| OzempicSemaglutide | 11 | $15,629 |
| Sucralfate | 17 | $1,486 |
| Nadolol | 13 | $432 |
| Omeprazole | 21 | $229 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadVemlidy | $377 | $27,95620 claims |
| Novo NordiskOzempic | $159 | $15,62911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 579 gastroenterology providers in Massachusetts.
Other gastroenterology in Boston
- Hiroyuki AiharaBoston$728K
- Jessica AllegrettiBoston$696K
- John LeungBoston$682K
- Ramnik XavierBoston$567K
- Adam CheifetzBoston$512K
- Carlo TraversoBoston$447K
- Tyler BerzinBoston$215K
- Marvin RyouBoston$162K
- Nneka UfereBoston$153K
- Christopher ThompsonBoston$127K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.